Johnson & Johnson (JNJ) is Boston Financial Mangement LLC’s 8th Largest Position

Boston Financial Mangement LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 3.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 221,553 shares of the company’s stock after selling 6,769 shares during the quarter. Johnson & Johnson makes up approximately 1.8% of Boston Financial Mangement LLC’s portfolio, making the stock its 8th largest position. Boston Financial Mangement LLC’s holdings in Johnson & Johnson were worth $26,883,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Financial Gravity Wealth Inc. bought a new position in Johnson & Johnson during the first quarter valued at about $105,000. WP Advisors LLC bought a new position in Johnson & Johnson during the second quarter valued at about $108,000. FNY Investment Advisers LLC bought a new position in Johnson & Johnson during the second quarter valued at about $117,000. Live Your Vision LLC grew its position in Johnson & Johnson by 58.3% during the second quarter. Live Your Vision LLC now owns 1,363 shares of the company’s stock valued at $172,000 after buying an additional 502 shares during the period. Finally, Signition LP bought a new position in Johnson & Johnson during the first quarter valued at about $204,000. Hedge funds and other institutional investors own 66.06% of the company’s stock.

In other Johnson & Johnson news, COO Michael E. Sneed sold 29,000 shares of the company’s stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the sale, the chief operating officer now directly owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Alex Gorsky sold 264,465 shares of the company’s stock in a transaction dated Friday, November 16th. The shares were sold at an average price of $145.96, for a total transaction of $38,601,311.40. Following the sale, the chief executive officer now directly owns 481,254 shares in the company, valued at $70,243,833.84. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 349,805 shares of company stock worth $50,593,707. Insiders own 0.22% of the company’s stock.

Several equities analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a research report on Tuesday. Citigroup increased their price target on shares of Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a research report on Monday, October 22nd. Credit Suisse Group increased their price target on shares of Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a research report on Wednesday, October 17th. Raymond James increased their price target on shares of Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a research report on Wednesday, October 17th. Finally, Wells Fargo & Co restated an “outperform” rating and set a $160.00 price target (up previously from $155.00) on shares of Johnson & Johnson in a research report on Wednesday, October 17th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $143.97.

NYSE JNJ opened at $142.23 on Friday. The stock has a market cap of $380.95 billion, a price-to-earnings ratio of 19.48, a price-to-earnings-growth ratio of 2.22 and a beta of 0.58. Johnson & Johnson has a 52 week low of $118.62 and a 52 week high of $148.75. The company has a current ratio of 1.72, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.03 by $0.02. The business had revenue of $20.35 billion for the quarter, compared to the consensus estimate of $20.05 billion. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The company’s revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.90 earnings per share. On average, analysts anticipate that Johnson & Johnson will post 8.16 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be issued a dividend of $0.90 per share. This represents a $3.60 annualized dividend and a yield of 2.53%. The ex-dividend date of this dividend is Monday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by WKRB News and is the property of of WKRB News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.wkrb13.com/2018/11/24/johnson-johnson-jnj-is-boston-financial-mangement-llcs-8th-largest-position.html.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: Stop Order Uses For Individual Investors

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply